Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chemodex
Olaparib
108
CHF
CHF 108.00
In stock
CDX-O0144-M100100 mgCHF 108.00
CDX-O0144-G0011 gCHF 474.00
| Product Details | |
|---|---|
| Synonyms | AZD 2281; Ku-0059436; Lynparza; 1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine |
| Product Type | Chemical |
| Properties | |
| Formula | C24H23FN4O3 |
| MW | 434.47 |
| CAS | 763113-22-0 |
| RTECS | TH9203962 |
| Source/Host Chemicals | Synthetic |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | Off-white to beige powder. |
| Solubility | Soluble in DMSO (20mg/ml) or DMF (10mg/ml). Slightly soluble in ethanol (1mg/ml). |
| Identity | Determined by 1H-NMR. |
| Declaration | Manufactured by Chemodex. |
| Other Product Data |
Click here for Original Manufacturer Product Datasheet |
| InChi Key | FDLYAMZZIXQODN-UHFFFAOYSA-N |
| Smiles | O=C(C1CC1)N2CCN(C(C3=C(F)C=CC(CC(C4=C5C=CC=C4)=NNC5=O)=C3)=O)CC2 |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Protect from light and moisture. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
Olaparib is a cell-permable potent inhibitor of PARP1 and PARP2 (IC50=5 and 1nM, respectively) but is less effective against the PARP tankyrase-1 (IC50=1.5μM). Some poly(ADP-ribose) polymerases (PARPs) assist in the repair of single-strand DNA nicks, an important step in base excision repair (BER), counteracting against DNA alkylating agents. Olaparib is a anticancer and chemotherapeutic agent (especially in cancers with BRCA mutations) that can be used in cells and in animals, alone or in combination therapy with alkylating agents, to block BER and increase cancer cell death.
Product References
(1) K.A. Menear, et al.; J. Med. Chem. 51, 6581 (2008) | (2) S. Rottenberg, et al.; PNAS 105, 17079 (2008) | (3) B.P. Rowe & P.M. Glazer; Breast Cancer Res. 12, 1 (2010) | (4) Y. Yuan, et al.; J. Hematol. Oncol. 4, 1 (2011) | (5) R. Plummer; Breast Cancer Res. 13, 1 (2011) | (6) M. Javle & N.J. Curtin; Ther. Adv. Med. Oncol. 3, 257 (2011) | (7) D. Davar, et al.; Curr. Med. Chem. 19, 3907 (2012) | (8) C.C. Gunderson & K.N. Moore; Future Oncol. 11, 747 (2015) | (9) F. De Felice, et al.; Drug Des. Devel. Ther. 11, 547 (2017) | (10) J. Stewart, et al.; Expert Rev. Anticancer Ther. 18, 947 (2018)